The Sepsis ImmunoScore™ is a pathogen-agnostic, host-based digital diagnostic that uses Artificial Intelligence/Machine Learning (AI/ML) to predict sepsis based on a combination of clinical parameters and protein biomarkers
CHICAGO, June 7, 2023 /PRNewswire/ — Prenosis Inc., an artificial intelligence company enabling precision medicine in acute care, announced today it has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), a U.S. government agency.
Prenosis has built a large, rapidly growing dataset and biobank from patients with sepsis and other infections. By leveraging its proprietary dataset and AI/ML techniques, Prenosis is creating precision medicine solutions, starting with a sepsis diagnostic tool. Prenosis’ Sepsis ImmunoScore™ intends to enable true precision medicine for infection in hospitals.
Sepsis kills more people worldwide than all cancers combined1. Early identification of patients at risk of sepsis is critical to administer timely interventions that improve patient outcomes, but doing so is challenging. The Sepsis ImmunoScore™ is a pathogen-agnostic, host-based digital diagnostic (HBD) that uses clinical parameters and protein biomarkers to assess a patient’s risk of sepsis within 24 hours. In a hospital environment, the Sepsis ImmunoScore™ integrates seamlessly into clinical workflow: (1) a patient enters a hospital or emergency department, (2) if an infection is suspected, a physician orders the Sepsis ImmunoScore™ test, (3) using deep biological profiling, the Prenosis AI analyzes the patient’s biology, and, (4) the Sepsis ImmunoScore™ appears on a screen within the hospital’s Electronic Medical Record (EMR) and provides actionable insights to enable optimized and personalized care for the patient.